Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Organisation › Details

Shire Ltd. (LSE: SHP, NASDAQ: SHPGY)

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. *

 

Period Start 2008-05-23 reorganised
  Group Takeda (Group)
  Predecessor Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ)
     
Region Region Dublin
  Country Ireland, Republic of
  City n. a. Dublin
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: 
     
   
Record changed: 2020-07-03

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Takeda (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC A October 650x80px




» top